Novocure's new system aims to make Optune therapy even easier for glioblastoma patients. Actor portrayal. (Photo: Business Wire) Novocure's second generation Optune system, at right, features a Tumor ...
The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Clinical Trials Arena on MSN
Novocure’s Optune Gio fails to show benefit at earlier stage
The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier.
Long-term data from the phase 3 EF-14 study showed that Optune plus temozolomide had a survival benefit compared to temozolomide alone. Adding Optune to temozolomide improved overall survival (OS) by ...
SHREVEPORT, La. (Press Release) - Willis-Knighton Cancer Center is now offering Optune, a medical device that, when used in conjunction with partial-brain radiotherapy and chemotherapy, has been shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results